Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
September 27 2023 - 4:15PM
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage
biopharmaceutical company translating genetic insights into the
development of therapies for central nervous system (CNS) disorders
characterized by neuronal excitation-inhibition imbalance, today
announced that it will host a R&D Day on Monday, October 2, at
9:00 a.m. EDT, virtually and in person in New York City.
During the event, Praxis’ management team will review progress
from its pipeline programs, including the anticipated initiation of
the Phase 3 program for ulixacaltamide in essential tremor and
advances in its clinical epilepsy assets.
Praxis’ management team will be joined by key opinion leaders in
Movement Disorders and Epilepsy, including Alberto J. Espay, M.D.,
MSc, FAAN, FANA, Professor and Endowed Chair of the James J. and
Joan A. Gardner Center for Parkinson’s Disease and Movement
Disorders at the University of Cincinnati, and Jacqueline French,
M.D., Professor of Neurology at NYU Grossman School of Medicine and
President, Director and Founder of the Epilepsy Study
Consortium.
To register for the event and view speaker profiles, please
visit our R&D Day webpage here. The event can also be accessed
from the Events & Presentations page of the Investors + Media
section of the company’s website at www.praxismedicines.com. A
replay of the event will be available through the Events &
Presentations page of the Investors + Media section of the
company’s website for 90 days following the event.
About PraxisPraxis Precision Medicines is a
clinical-stage biopharmaceutical company translating insights from
genetic epilepsies into the development of therapies for CNS
disorders characterized by neuronal excitation-inhibition
imbalance. Praxis is applying genetic insights to the discovery and
development of therapies for rare and more prevalent neurological
disorders through our proprietary small molecule platform,
Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™,
using our understanding of shared biological targets and circuits
in the brain. Praxis has established a diversified, multimodal CNS
portfolio including multiple programs across movement disorders and
epilepsy, with four clinical-stage product candidates. For more
information, please visit www.praxismedicines.com and
follow us
on Facebook, LinkedIn and Twitter/X.
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452
Media Contact:
Ian Stone
Evoke Canale
Ian.stone@evokecanale.com
619-849-5388
Praxis Precision Medicines (NASDAQ:PRAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Praxis Precision Medicines (NASDAQ:PRAX)
Historical Stock Chart
From Sep 2023 to Sep 2024